Drug intelligence / Profile preview

gatifloxacin + prednisolone

Development stage
Unknown
Lead developer
Globus Remedies
Modality
Small Molecules
Administration
Ophthalmic, Otic
01

Overview

Gartin Plus is a fixed-dose combination pharmaceutical product developed and marketed by Globus Remedies, primarily available as an ophthalmic or otic suspension. It combines gatifloxacin, a fourth-generation fluoroquinolone antibiotic, with prednisolone acetate, a synthetic glucocorticoid. Gatifloxacin provides broad-spectrum antibacterial activity by inhibiting the enzymes DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication, transcription, and repair. Prednisolone acetate serves as an anti-inflammatory agent, reducing swelling, redness, and itching by agonizing the glucocorticoid receptor and modulating the expression of inflammatory mediators. The combination is indicated for treating bacterial infections of the eye or ear accompanied by inflammation, such as bacterial conjunctivitis or keratitis.

Brand names
Gartin Plus
Other names
Gatifloxacin and Prednisolone Acetate Ophthalmic Suspension
02

Targets

GR (Glucocorticoid receptor)TOP2 (DNA topoisomerase 2)DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on gatifloxacin + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gatifloxacin + prednisolone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call